• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Abstract A process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate and, optionally, saccharin sodium and/or orange flavour; products, intermediate products, and uses thereof.
    公开号:AU2013204452A1
    申请号:U2013204452
    申请日:2013-04-12
    公开日:2013-05-09
    发明作者:Tiejun Diao；Haijun Xu
    申请人:Ferring International Center SA；
    IPC主号:A61K9-14
    专利说明:
    Docunint9-12/04/2013 Process for the manufacture of a pharmaceutical product This application is a divisional of Australian Patent Application No. 2008309287, the entire content of which is incorporated herein by reference. The present invention relates to an improved process for the manufacture of a pharmaceutical product, and products and intermediate products resulting therefrom. BACKGROUND OF THE INVENTION A pharmaceutical product used for clearance of the bowel prior to X-ray examination, endoscopy or surgery, is presently sold under the trade mark name of PICOLAXTM. The pharmaceutical product is a white powder which is made up as a solution (in water) for administration. The properties required are that it is a strong laxative that is easily palatable. The pharmaceutical product includes sodium picosulphate (PS), a stimulant laxative; and anhydrous citric acid (CA) and magnesium oxide (MgO, light), which together in solution form magnesium citrate, an osmotic laxative with a powerful cathartic effect. The dosage form for oral delivery is in the form of granules. Herein the term granule(s) includes loose particles (such as particles which might collectively be termed a powder, including loose particles in the form of a powder which is known in the art as "powder for oral administration"). The product is a physical mixture of six raw materials; these being citric acid (e.g. citric acid anhydrous or citric acid monohydrate), magnesium oxide (e.g. magnesium oxide light), potassium bicarbonate (KHCO 3 ), sodium picosulphate (NaPIC), sodium saccharin, and orange flavour. Magnesium oxide "light" means, herein, magnesium oxide having an apparent volume such that 15g occupies bewteen 75 to 180ml, e.g 15g occupies a volume of 150ml. The known process for making PICOLAXTM may include the following steps. Granules of magnesium oxide and citric acid are - 1 - WO 2009/047633 PCT/IB2008/003199 produced by mixing the two reagents together - this is known as the "primary mix". In another stage, potassium bicarbonate, sodium picosulphate and water are mixed or blended to produce a wet "pre-mix", which is then dried. In a further stage, the flavour ingredients, orange 5 flavour and sodium saccharin, are blended with the pre-mix and primary mix. The known process has several associated problems. Firstly, the mixing processes may result in inhomogeneity problerns in the final and intermediate products. In one aspect, the terms 10 "inhomogeneity" and "lack of homogeneity" as used in this application refer to the lack of uniformity of content of the active substance - sodium picosulphate - in e.g. the final product. It also refers to the lack of homogeneity in the physical and morphological properties, such as the particle size (diameter) or particle size range or distribution, of the 15 intermediate products and/or the final product granules. Intermediate product granules are, for example the primary mix granules or the pre-mix granules. Homogeneity has been suspected to be at least one of the critical 20 factors assuring the quality and performance of the final product, and it is believed that product homogeneity (and inhomogeneity) relates to the mixing processes used. Thus, in the first stage of the known process, disparities may occur in the granule size and distribution (i.e. inhomogeneity may arise) because of the low binding properties or 25 agglomeration properties between citric acid and magnesium oxide particles (caused by e.g the difference in densities of the two materials). Further, magnesium oxide is left on the mixer bowl, blades etc. (rather than being mixed with the citric acid). Thus, in the known process, extra magnesium oxide ("overage") is included in the raw materials to 30 compensate for losses during the blending process. The overage is typically over 10%. This leads to economic losses over longer periods and where larger quantities are produced. Additionally, longer processing 2 WO 2009/047633 PCT/IB2008/003199 times are entailed, and unhealthy amounts of dust may be produced during mixing. In the premix stage, lack of homogeneity of the resulting granules 5 may arise due to dissolution of some potassium bicarbonate in the granulation medium, water, and because of physical degradation (smashing) of the particles during mixing. This may have a detrimental effect on the final product. Further, long processing times, and multiple steps, are required to complete this stage of the process (which takes 10 typically 15 to 24 hours). Thus, there is a need for an improved manufacturing process. SUMMARY OF THE INVENTION 15 The present applicants have developed a process which may alleviate some or all of the problems of the prior art process, and e.g. provide an improved product and/or a marked reduction in processing time. 20 There is provided therefore, according to an aspect of the present invention, a process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate 25 and, optionally, saccharin sodium and/or orange flavour, comprising: a) dry mixing citric acid and magnesium oxide; b) applying (e.g. spraying) a solution of sodium picosulphate onto the potassium bicarbonate; and drying said sodium picosulphate and potassium bicarbonate; and 30 c) mixing at least a part of the product of step a) with at least a part of the product of step b) and, optionally, saccharin sodium and/or orange flavour. 3 WO 2009/047633 PCT/IB2008/003199 In one example, the process includes a further step d) of mixing the product of step c) with further amount of a mixture formed by dry mixing citric acid and magnesium oxide [e.g. some or all of the remaining product 5 of the process defined in step a)]; and/or a product formed by applying (e.g. spraying) a solution of sodium picosulphate on to potassium bicarbonate and drying the sodium picosulphate and potassium bicarbonate [e.g. some or all of the remaining product of the process defined in step b)]. 10 Thus, in one aspect there is provided a process for the preparation of a pharmaceutical composition, comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate and, optionally, saccharin 15 sodium and/or orange flavour, comprising: a) dry mixing citric acid and magnesium oxide; b) applying (e.g. spraying) a solution of sodium picosulphate onto the potassium bicarbonate; and drying said sodium picosulphate and potassium bicarbonate; 20 c) mixing at least a part of the product of step a) with at least a part of the product of step b) and, optionally, saccharin sodium and/or orange flavour; and d) mixing the product of step c) with some or all of the remaining product of the process defined in step a); and/or some or all of 25 the remaining product of the process defined in step b). The product homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosuiphate and, optionally, saccharin sodium and/or orange flavour may 30 be in the form of granules. The granule(s) may have a particle size (diameter) range or distribution of between about 100 and about 900 pm, e-g. between about 150 and 875 pm, eg. between about 250 and about 4 WO 2009/047633 PCT/IB2008/003199 850 pm. The pharmaceutical composition may be in the form of granules of e.g. a particle size (diameter) range or distribution of between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 um. 5 It will be appreciated that herein the term diameter is not intended to mean that any of the particles and granules disclosed are spherical. As is clearly shown in the attached drawings the granules may be, for example, roughly spherical, in the form of elongated spheres (ellipsoidal) 10 etc. Herein the term size (diameter) is intended to mean the shortest distance in a straight line passing from one side to the other through the centre point of the granule (e.g. sphere, rough sphere, elongated sphere, ellipsoid). 15 According to the present invention in a further aspect, there is provided a granule or granules or a pharmaceutical composition, comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate, and, optionally, saccharin sodium, and orange flavour. The pharmaceutical 20 composition of the present invention may be used for clearance of the bowel prior to X-ray examination, endoscopy or surgery. The granule(s) may have a particle size (diameter) range or distribution of between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 pm. 25 Said granules) or pharmaceutical composition may be dispensed as sachets. The uniformity of content of the active substance, sodium picosuiphate, in the final product granule(s) or pharmaceutical composition 30 may have a mean value of about 0.0559% and 0.068% by weight (9.0 11.0 mg/dose, based on a dose of 16.1g PICOLAXTM), 5 WO 2009/047633 PCT/IB2008/003199 According to the present invention in a further aspect, there is provided a pharmaceutical preparation or pharmacetical composition comprising product granules of a homogeneous or substantially homogeneous mixture of a first composition comprising (first) granules of 5 citric acid and magnesium oxide as described herein (e.g. comprising granules including citric acid and magnesium oxide, the granules comprising a layer of magnesium oxide coated on a core of citric acid); and a second composition comprising (second) granules of potassium bicarbonate and sodium picosulphate as described herein (e.g. comprising 10 granules including sodium picosulphate and potassium bicarbonate, the granules comprising a layer of sodium picosulphate coated on a core of potassium bicarbonate); and, optionally, saccharin sodium and/or orange flavour. The product granule(s) may have a particle size (diameter) range between about 100 and about 900 pm. The product granule(s) may have 15 a uniformity of content of sodium picosulphate of mean value between about 0.0559% and 0.068% by weight. The process of the invention may include a separation (e.g. processing e.g. sieving) step or steps e.g. to obtain potassium bicarbonate 20 of appropriate size and/or size distribution - e.g. a particle size (diameter) range of, for example, between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 pm - prior to applying (e.g. spraying). The process of the invention may include a separation (e.g. processing e.g. sieving) step or steps e.g. to 25 obtain citric acid of appropriate size and/or size distribution - e.g. a particle size (diameter) range of, for example, between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 pm - prior to mixing with magnesium oxide. 30 The present invention also provides a process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium 6 WO 2009/047633 PCT/IB2008/003199 bicarbonate and sodium picosuIlphate and, optionally, saccharin sodium and/or orange flavour (and/or a process for the preparation of a composition comprising citric acid and magnesium oxide) comprising a step of dry mixing citric acid and magnesium oxide (e.g. magnesium oxide 5 light), using a means for forming a homogeneous mixture of compounds with markedly different densities (such as a multi-dimension blender or three-dimensional blender). The means may mix using a three dimensional motion (e.g. that known as the Paul Schatz principle). The means may mix using a three-dimensional motion which combines a 10 figure-of-eight movement with rotation, causing the substances within the mixer to move in a rhythmic, pulsating motion. The means may enhance the agglomeration process between citric acid and magnesium oxide. The means (e.g. multi-dimension blender or three-dimensional blender) may be closed during mixing, which may prevent dust or contamination. The 15 means (e.g. multi-dimension blender or three-dimensional blender) may mix by an action whereby the mixing vessel is agitated or moved (e.g. spun) with a three dimensional motion, rather than by the use of a blade or paddle within the vessel (as in a conventional, planetary, mixer). The three dimensional motion may reduce particle damage (and inconsistent 20 product size) associated with conventional mixing techniques - e.g. caused by frictional forces between the blade or paddle and mixing vessel side. The citric acid may be loaded e.g. in a single batch into the means 25 for forming a homogeneous or substantially homogeneous mixture of compounds with markedly different densities (such as a multi-dimension blender or three-dimensional blender), prior to addition of magnesium oxide. The magnesium oxide may be added in e.g. two to six, e.g. four, batches, with mixing between addition of each batch. The addition of MgO 30 in small batches to the full amount of citric acid, and the mixing in between each addition of a batch of MgO, may enhance the agglomeration process WO 2009/047633 PCT/IB2008/003199 between citric acid and magnesium oxide, and/or the homogeneity of the product mixture, and/or reduce the loss of MgO. The process may include a separation (e.g. processing e.g. sieving) 5 step or steps e.g. to obtain citric acid of appropriate size and/or size distributiuon - e.g. a particle size (diameter) range of, for example, between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 pm - prior to mixing with magnesium oxide. The process optionally includes one or more 10 separation (e.g. sieving) steps e.g. to obtain product composition/granules of appropriate size (diameter) and/or size distribution. The (product) composition/granules may have a particle size (diameter) and/or particle size (diameter) distribution which is compatible 15 with the particle size or particle size distribution of the pre-mix or with the product of a step of applying (e.g. spraying) sodium picosulphate on potassium bicarbonate and drying. According to a further aspect of the invention, granules (e.g. 20 granules which are agglomerated particles) of citric acid and magnesium oxide are provided, having a particle size distribution range of between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 pm. The granules may have a particle size (diameter) distribution wherein more than 85%, for example more 25 than 90%, for example more than 92% of the particles have a particle size (diameter) between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 pm. The granules may have a particle size (diameter) distribution wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a 30 particle size (diameter) greater than about 850 tm; and/or wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a particle size (diameter) less than about 250 pm. The 8 WO 2009/047633 PCT/IB2008/003199 granules may have a particle size (diameter) distribution wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a particle size (diameter) greater than about 875 pm; and/or wherein less than 5%, for example less than 2%, for example less than 1% of the 5 particles have a particle size (diameter) less than about 150 lim. The granules may have a particle size (diameter) distribution wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a particle size (diameter) greater than about 900 pm; and/or wherein less than 5%, for example less than 2%, for example less than 1% of the 10 particles have a particle size (diameter) less than about 100 pm. The granules may have a particle size (diameter) range of, for example, between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 pm. The granules may have size or size distribution which is compatible with mixing with the product of 15 a step of applying (e.g. spraying) a solution of sodiurn picosulphate on to potassium bicarbonate; and drying the sodium picosulphate and potassium bicarbonate (e.g. step b), The granules may include a layer of magnesium oxide coated on the citric acid. 20 According to a further aspect of the invention, there is provided a composition comprising granules including citric acid and magnesium oxide, the granules comprising a layer of magnesium oxide coated on a core of citric acid. The thickness of the layer of magnesium oxide may be between 2 and 15 pm, for example between 5 and 10 pm. The granules 25 may be between 450 and 800 pm broad (e.g. 500 to 700 pm broad) at their broadest point [i.e. at the longest distance in a straight line passing from one side of the granule to the other through the centre point of the granule (e.g. sphere, rough sphere etc.). In a further aspect, the present invention provides a process for the 30 preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosuiphate and, optionally, saccharin 9 WO 2009/047633 PCT/IB2008/003199 sodium and/or orange flavour, (and/or a process for the preparation of a composition comprising potassium bicarbonate and sodium picosuiphate,) comprising a step of applying (e.g. spraying) a solution of sodium picosulphate on to the potassium bicarbonate; and drying the sodium 5 picosulphate and potassium bicarbonate. The potassium bicarbonate may have a particle size (diameter) range of, for example, between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 10 pm. The process may include a separation (e.g. sieving) step or steps e.g. to obtain potassium bicarbonate of appropriate size and/or size distribution - e.g. a particle size (diameter) range of, for example, between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 pm. 15 The sodium picosulphate may be in aqueous solution. The ratio by weight of sodium picosulphate:water in the solution may be between 1:1 and 1:3, for example between 1:1.3 and 1:2.5, for example between about 1:1.5 and 1:2. The sodium picosulphate solution - e.g. aqueous solution 20 may be applied (e.g. sprayed) at a rate of I to 20 mi/min, preferably 10 to 12 mI/min. In one example the sodium picosuIlphate is in aqueous solution. The solution - e.g. aqueous solution - may be applied (e.g. sprayed) onto 25 the surface of e.g. granules or particles of potassium bicarbonate. The solution - e.g. aqueous solution - may be applied (e.g. sprayed) as e.g. micro-liquid drops. The potassium bicarbonate may be preheated (e.g. prior to applying 30 (e.g. spraying) the solution of sodium picosulphate on to the potassium bicarbonate) e.g. to a temperature of between 300 to 100 C, e.g. 39 C to 70'C, e.g. 30 'C to 50 0 C. The sodium picosulphate and potassium 10 WO 2009/047633 PCT/IB2008/003199 bicarbonate may be dried at e.g. a temperature of between 300 to 100 0 C, e.g. 30'C to 70*C, e.g. 30 OC to 500C, for example 450C. The drying may be by using [e.g. applying e.g. blowing warm or hot air (e.g. at a temperature of between 300 to 100 C, e.g. 30 *C to 70*C, e.g. 30 OC to 5 500C). The drying may be during applying (e.g. spraying), and/or immediately or substantially immediately after applying (e.g. spraying). There may be one or more (e.g. 2, 3, 4 or more) applications (by e.g. spraying) of sodium picosulphate solution, the sodium picosuiphate and potassium bicarbonate being dried during or immediately or substantially 10 immediately after each (spray) application. The applying (e.g. spraying) and drying may be performed e.g. in a tumble coating machine, or other coating machine (e.g. fluid bed coating machine) known to the skilled man. 15 The applying (e.g. spraying) and drying of sodium picosulphate and potassium bicarbonate may thus be finished in one step using the same coating machine instead of requiring two or more separate (mixing, drying) steps, and/or two or more separate machines. 20 The process may be auto-controlled. Thus, manual operations may be avoided, again allowing a reduction in the total process time. The process may include a separation (e.g. sieving) step or steps to 25 obtain product of appropriate size and/or size distribution- e.g. a particle size (diameter) range of, for example, between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 pm. 30 The (product) composition comprising potassium bicarbonate and sodium picosulphate may have a particle size (diameter) and/or particle size (diameter) distribution which is compatible with the particle size or 11 WO 2009/047633 PCT/IB2008/003199 particle size distribution of the primary mix or product of the step of dry mixing citric acid and magnesium oxide. The (product) composition comprising potassium bicarbonate and sodium picosulphate may have a particle size (diameter) distribution wherein more than 85%, for example 5 more than 90%, for example more than 92% of the particles have a particle size (diameter) between about 100 and about 900 pm, e.g. between about 150 and 875 um, e.g. between about 250 and about 850 pm. The (product) composition comprising potassium bicarbonate and sodium picosulphate may have a particle size (diameter) distribution 10 wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a particle size (diameter) greater than about 850 [im; and/or wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a particle size (diameter) less than about 250 pm. The (product) composition comprising potassium bicarbonate 15 and sodium picosulphate may have a particle size (diameter) distribution wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a particle size (diameter) greater than about 875 pm; and/or wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a particle size (diameter) less than about 20 150 am. The (product) composition comprising potassium bicarbonate and sodium picosulphate may have a particle size (diameter) distribution wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a particle size (diameter) greater than about 900 11m; and/or wherein less than 5%, for example less than 2%, for example less 25 than 1% of the particles have a particle size (diameter) less than about 100 fpm. The (product) composition comprising potassium bicarbonate and sodium picosulphate may have a particle size (diameter) range or distribution of, for example, between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 30 um. 12 WO 2009/047633 PCT/IB2008/003199 The product or composition formed by applying (e.g. spraying) a solution of sodium picosulphate on to potassium bicarbonate and drying may be in the form of granules or particles, possessing improved homogeneity. 5 According to the present invention in a further aspect there is provided a composition comprising granules including sodium picosulphate and potassium bicarbonate, the granules comprising a layer of sodium picosulphate coated on a core of potassium bicarbonate. The 10 granules may be e.g. substantially ellipsoidal [e.g. in the shape of an elongated sphere (see e.g. Fig 2)). The granules may be substantially ellipsoidal in shape with the shortest distance in a straight line passing from one side of the granule to the other through the centre point of the granule being between 100 and 500 pm (e.g. 200 to 400 pm); and/or with 15 the longest distance in a straight line passing from one side (end) of the granule to the other through the centre point of the granule being between 500 and 900 pm (e.g. 550 to 750 pm). 20 According to another aspect of the invention, pre-mix granules of sodium picosulphate and potassium bicarbonate, having a particle size (diameter) range or distribution of between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 pm, are provided. 25 According to another aspect of the invention there is provided a granule or granules comprising a layer of sodium picosulphate coated on potassium bicarbonate, The granules may have a particle size (diameter) distribution wherein more than 85%, for example more than 90%, for 30 example more than 92% of the particles have a particle size (diameter) between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 pm. The granules may have 13 WO 2009/047633 PCT/IB2008/003199 a particle size (diameter) distribution wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a particle size (diameter) greater than about 850 pm; and/or wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a 5 particle size (diameter) less than about 250 pm. The granules may have a particle size (diameter) distribution wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a particle size (diameter) greater than about 875 pm: and/or wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a 10 particle size (diameter) less than about 150 um. The granules may have a particle size (diameter) distribution wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a particle size (diameter) greater than about 900 pm; and/or wherein less than 5%, for example less than 2%, for example less than 1% of the particles have a 15 particle size (diameter) less than about 100 um. The granules may have a particle size (diameter) range of, for example, between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 pm, 20 The pre-mix granules produced by methods of the present invention may possess a content of uniformity of sodium picosulphate (mg dose) which contributes to the homogeneity of final product. The present invention may provide, an intermediate composition or pre-mix, comprising potassium bicarbonate and sodium picosuIlphate, in the form of granules, 25 which have a specified content of uniformity of sodium picosulphate (mg dose) which is consistent with that of the final product granule(s) or pharmacutical composition (see above) and a particle size (diameter) range of between between about 100 and about 900 pm, e.g. between about 150 and 875 pm, e.g. between about 250 and about 850 pm. 30 14 WO 2009/047633 PCT/IB2008/003199 It will be appreciated that herein process steps may be referred to as step a), b), c) etc. for clarity only; there is no express or implied requirement regarding ordering of steps. Thus, for example, the step a) process may be completed before, after, or substantially simultaneously 5 with step b). DETAILED DESCRIPTION OF THE INVENTION The present invention will now be illustrated with reference to the 10 following Examples and the attached drawings in which FIGURE 1 shows SEM picures and EDAX analysis results for Primary Mix granules of citric acid and magnesium oxide according to an embodiment of the invention: and FIGURE 2 shows SEM picures and EDAX analysis results for Pre Mix granules of sodiurn picosulphate and potassium bicarbonate according to 15 an embodiment of the invention. The product PICOLAXTM is a physical mixture of six raw materials; these being citric acid (anhydrous), magnesium oxide, light, potassium bicarbonate (KHCO3), sodium picosulphate, saccharin sodium, and orange 20 flavour. In the first stage of the known process for making PICOLAX TM, as discussed above, the "primary mix" comprising magnesium oxide and citric acid, is first produced- Extra magnesium oxide ("overage") is measured in 25 as part of the feed to compensate for losses during the blending process. In the second stage, potassium bicarbonate, sodium picosulphate and water are mixed or blended to produce the "pre-mix". The pre-mix granulate is then dried. In the third stage, the flavour ingredients, orange flavour and sodium saccharin, are blended with the pre-mix and the 30 primary mix, According to the present invention in some aspects, the process also requires several stages. 15 WO 2009/047633 PCT/IB2008/003199 The Primary Mix In the prior art process, disparities were found to occur in the granule size and distribution, apparently due to the low binding properties 5 or agglomeration properties between the citric acid and magnesium oxide particles. The prior art equipment employed, which was typically a tumble blender or planetary dry mixer, appeared to encourage separation of the two components, and loss of raw material in the form of fines, for example, of magnesium oxide. Using the known process, it is necessary to 10 compensate on a regular basis for losses by adding extra magnesium oxide ("overage") in an amount of typically above 10%, which leads to economic losses over longer periods and larger quantities produced. Additionally, long processing times may be entailed, and unhealthy amounts of MgO dust may be produced during mixing. The prior art 15 process may result in cleaning difficulties, and/or poor control of product granule/particle size and distribution. A stage or step of present invention involves dry mixing of citric acid (CA) and magnesium oxide, to produce the "primary-mix". In contrast to 20 the prior process, a better-agglomerated mixture may be obtained by mixing the citric acid and magnesium oxide using e.g. a multi-dimension blender or three-dimensional blender. The overage is significantly less. Three-dimensional blenders are known and may be obtained from e.g. Laval Lab Inc., of the US. The mixing vessel is moved using a three 25 dimensional motion (known as the Paul Schatz principle) which combines a figure-of-eight movement with rotation, causing the substances within the mixer to move in a rhythmic, pulsating motion. This motion may mix powders and granulates of differing weights, sizes and flow properties. 30 The multi-dimension blender utilizes strong physical force in the absence of a blade to mix materials, rather than a mechanical stirring agitator (as in a planetary dry mixer). This may reduce particle damage 15 WO 2009/047633 PCT/IB2008/003199 (and inconsistent product size) caused by frictional forces between the agitator blade or paddle and mixing vessel side. It also reduces dust from particle damage which is believed to affect the homogeneity of the final product, and/or sticking onto the mixing vessel internal wall. Further, 5 cleaning is much easier because there is only the smooth interior surface to clean (no stirring agitator to clean). The use of the multi-dimension blender or three-dimensional blender is accompanied by appropriate adjustments to the operational 10 parameters, such as rotation speed, mixing time and material adding frequency. The new process thus removes or significantly reduces the problems encountered in the prior process. 15 The Pre-Mix In, the second stage of the prior process, when producing the pre mix, the sodium picosulphate was wet mixed with potassium bicarbonate. During wet mixing, a part of the potassium bicarbonate was dissolved, and 20 part was smashed by the stirring agitator; these actions resulted in excess fine powder of potassium bicarbonate in the pre-mix after drying. A loss of product homogeneity was believed to result from this, because overly large particles or granules contain less sodium picosulphate, while overly fine particles or granules of the dried mixture contain too much sodium 25 picosulphate; these extremes were believed to affect product homogeneity. The known process also required that the wet mixture was dried for a significant period. The known process also required several manual steps with the attendant risk of contamination to the product and increased operator safety concerns. 30 According to one or more aspects of the present invention, the process includes a step of applying (eg. spraying) a solution of sodium 17 WO 2009/047633 PCT/IB2008/003199 picosulphate on to the potassium bicarbonate; and drying the sodium picosuiphate and potassium bicarbonate. This process for mixing may be thought of as akin to a coating 5 process. The mixing/coating process may be carried out using an automatic turnble coating machine, e.g. with appropriate adjustments to the operational parameters made to control the coating level. Thus, the solution (e.g. aqueous solution) of sodium picosulphate 10 may be sprayed onto the potassium bicarbonate; and the said sodium picosulphate and potassium bicarbonate (i.e, the coated pre-mix granules) may be dried in the same equipment. This may lead to a significantly reduced production time; for example, the "pre-mix" of sodium picosulphate and potassium bicarbonate may be produced in about 3 15 hours [rather than about 15 to 24 hours using the prior process]. Further, the applicants found that there may be a significant reduction in inhomogeneity in the product granules, as follows. The sodium picosulphate solution may be sprayed very evenly onto the surface 20 of the KHCO 3 granules and dried immediately after applying (e.g. spraying), and the amount of fine powder may be reduced. The granules are less likely to be reduced through, for example, smashing of particles/granules during a coating-type process. Further, because the coated granules may be dried instantly or substantially instantly e.g. with 25 warm air, fine powder and dust may be significantly diminished, Subsequently, the process of the invention may involve mixing of saccharin sodium, orange flavour, part of the primary mix and the pre-mix, with subsequent combination with the balance of the primary mix (and 30 mixing) to provide the final homogeneous bulk product. 18 WO 2009/047633 PCT/IB2008/003199 Thus, the disclosed invention may provide significant improvement in one, two, or more, steps in the mixing process. It may provide a more efficient process, of improved quality and reproducibility (e.g. with respect to uniformity of active substance). It may provide a method with reduced 5 risk of contamination and/or loss of material, and/or with less manual operation. It may provide a method incurring significantly reduced process time. The process according to the present invention may improve the 10 homogeneity of the intermediate products of the primary mix and pre-mix mixing stages, as well as final product. The present invention is now described with reference to the following examples. 15 EXAMPLE I - Method Potassium Bicarbonate is sifted on sieves with screen size of 250pm and 600pm. Purified water is weighed out and Sodium Picosulphate is dissolved in the water to form a sodium picosulphate solution for the Pre 20 Mix stage. Sodium picosulphate solution and potassium bicarbonate are formed into a granulate by using a tumble coater (such coaters are well known in the art). Potassium Bicarbonate granules are filled into the coater, and a defined amount of Sodium Picosulphate solution is sprayed onto the surface of the granules during operation of the coater. The coated 25 particles are then dried by warm air. After the coating process, pre-mix dried granules of combined Sodium Picosulphate and Potassium Bicarbonate are obtained. Fig 2 shows SEM pictures and EDAX results for a premix granule made by this method. 30 Magnesium Oxide and Citric Acid are mixed to form primary mix granules by using a three-dimensional dry blender. Citric Acid is filled into the blender, and Magnesium Oxide, light is added. The materials in the 19 WO 2009/047633 PCT/IB2008/003199 blender are mixed by the usual operating method. Fig 1 shows SEM pictures and EDAX results for a primary mix granule made by this method. Orange flavour and Sodium Saccharin are blended together with Pre-mix 5 and a known quantity of Primary mix to form a flavour blend. The flavour blend is then combined with the balance of Primary mix and mixed. The combined Final Blend powder is filled into foil sachets and packaged into cardboard boxes, using methods known in the art. 10 It is noted that the skilled man would readily understand the amount of reagent quantities etc to be used (for ex., in a larger scale production process) depending on the amount of product desired, Example 2 - Formulations 15 The following formulations were made by the method described above. Each foil sachet contains the following ingredients. Reagent Example 2a Example 2b Example 2c (16.1g sachet) Sodium 9mg 10mg 11mg picosulphate Potassium 0.45g 0.g 0.55g hydrogencarbonate , Magnesium oxide, j 3.15g 3.5g 3.85g light Citric acid 10.8g 12g 13.2 Saccharin sodium 54mg 60mg 66mg I Orange flavour* 54mg 60mg--6mg ___ __ I_____ __ 66mg natural spray dried orange flavour which includes buty ated hydroxyanisole 20 20 WO 2009/047633 PCT/IB2008/003199 Example 3 - SEM pictures and EDAX analysis results The SEM and EDAX pictures were taken at the Electron Microscope Lab at the Instrumentation Analysis and Research Centre, Sun Yat-sen University, China. 5 FIGURE 1 shows SEM picures and EDAX analysis results for a Primary Mix granule of citric acid and magnesium oxide according to an embodiment of the invention, made by the method of Example 1 10 These pictures show that the element MgO is found on the outer shell of the granule. The black and white photo (Electron Image 1) shows a roughly spherical granule, which has been cut on a plane to show the core of the granule and the shell. The other photo (Mg Ka 1_2) shows the positon of element Mg (the brighter/whiter dots). Comparing the two 15 photos, it is evident from the cut away section that the core of the granule has very little element MgO (the trace amount being due to contamination during cutting the sample in the preparation process for EDAX), while the shell includes a large quantity of MgO. The Sum Spectrum shows the sum of element MgO on the surface of the granule (the cut section and the 20 shell). Further, the black and white photo shows clearly that the granule has a crystal core of Citric Acid and a white shell of MgO. The layer thickness of the MgO shell may be calculated from the black and white photo (e.g. 25 using a ruler) to be 5-10 um. FIGURE 2 shows SEM picures and EDAX analysis results for a Pre Mix granule of sodium picosulphate and potassium bicarbonate according to an embodiment of the invention, made by the method of Example 1. 30 The pictures show that the element S (i.e, Sodium Picosulfate) is clearly detected on the shell and the element K (i.e. Potassium Bicarbonate) is 21 Docunint9-12/04/2013 clearly detected on the core. The black and white photo (Electron Image 1) shows a Pre Mix granule which has been cut away to show the core of the granule and the shell of the granule. The photo S Ka 1 shows the position of element S on the granule (dots). It is evident that most element S occupies the shell; the little quantity of element S on the cut section plane is contamination caused by the cutting operation in the sample preparation process for EDAX. The photo K Ka 1 shows the position of element K on/in the granule (dots); it can be seen that the cut section plane (the core of the granule) has more of element K than the shell. K Ka 1 and S Ka 1 confirm that the shell includes both element K and S, indicating that the layer of Sodium Picosulfate is very thin (because its quantity is very low - only 2% according to this formulation of Pre-Mix). The black and white photo shows clearly that the granule has a (crystal) core of Potassium bicarbonate and a (white) shell of Sodium Picosulfate. The granule may be described as substantially ellipsoidal. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates. - 22 -
    权利要求:
    Claims (48)
    [1] 1. A process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate 5 and, optionally, saccharin sodium and/or orange flavour comprising a step of applying (e.g. spraying) a solution of sodium picosulphate on to the potassium bicarbonate; and drying the sodium picosulphate and potassium bicarbonate. 10
    [2] 2. A process for the preparation of a composition comprising potassium bicarbonate and sodium picosulphate comprising a step of applying (e.g. spraying) a solution of sodium picosulphate on to the potassium bicarbonate; and drying the sodium picosulphate and potassium bicarbonate. 15
    [3] 3. A process according to claim 1 or 2 wherein the potassium bicarbonate has a particle size (diameter) range of between about 100 gm and about 900 jm. 20
    [4] 4. A process according to claim 1, 2 or 3 wherein the potassium bicarbonate is preheated prior to applying (e.g. spraying) the solution of sodium picosulphate on to the potassium bicarbonate.
    [5] 5. A process according to any preceding claim wherein the sodium 25 picosulphate and potassium bicarbonate are dried at a temperature of between 30 to 1000C,
    [6] 6. A process according to any preceding claim wherein the drying is during applying (e.g. spraying), and/or immediately or substantially 30 immediately after applying (e.g. spraying). 23 WO 2009/047633 PCT/IB2008/003199
    [7] 7. A process according to any preceding claim wherein there are two or more applications of sodium picosulphate solution, the sodium picosulphate and potassium bicarbonate being dried during or immediately or substantially immediately after each application. 5
    [8] 8. A process according to any preceding claim wherein the product or composition formed by applying (e.g. spraying) a solution of sodium picosulphate on to potassium bicarbonate and drying is in the form of granules or particles. 10
    [9] 9. A process according to claim 8 wherein the granules or particles have a particle size (diameter) distribution wherein more than 85% of the particles have a particle size (diameter) between about 100 pm and about 900 pm. 15
    [10] 10. A process according to claim 8 or 9 wherein the granules or particles have a particle size (diameter) distribution wherein less than 5% of the particles have a particle size (diameter) greater than about 900 pim; and/or wherein less than 5% of the particles have a particle size (diameter) 20 less than about 100 pm.
    [11] 11. A process according to any preceding claim wherein the sodium picosuiphate is in aqueous solution. 25
    [12] 12. A composition comprising potassium bicarbonate and sodium picosulphate formed by a process according any of claims 2 to 11,
    [13] 13. A composition comprising granules of sodium picosulphate and potassium bicarbonate, having a particle size (diameter) range or 30 distribution of between about 100 pm and about 900 pm. 24 WO 2009/047633 PCT/IB2008/003199
    [14] 14. A composition comprising granules including sodium picosulphate and potassium bicarbonate, the granules comprising a layer of sodium picosulphate coated on a core of potassium bicarbonate. 5
    [15] 15. A composition according to claim 14 wherein the granules have a particle size (diameter) distribution wherein more than 85% of the particles have a particle size (diameter) between about 100 pm and about 900 [tm.
    [16] 16. A composition according to claim 14 or 15 wherein the granules have a 10 particle size (diameter) distribution wherein less than 5% of the particles have a particle size (diameter) greater than about 900 ptm; and/or wherein less than 5% of the particles have a particle size (diameter) less than about 100 im. 15
    [17] 17. A process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate and, optionally, saccharin sodium and/or orange flavour comprising a step of dry mixing citric acid and magnesium oxide using a means for forming a 20 homogeneous mixture of compounds with markedly different densities.
    [18] 18. A process for the preparation of a composition comprising citric acid and magnesium oxide, comprising a step of dry mixing citric acid and magnesium oxide using a means for forming a homogeneous mixture of 25 compounds with markedly different densities.
    [19] 19. A process according to claim 17 or claim 18 in which the means for forming a homogeneous mixture of compounds with markedly different densities is a multi-dimension blender or three-dimensional blender. 30 25 WO 2009/047633 PCT/IB2008/003199
    [20] 20. A process according to claim 17, 18 or 19 in which the means enhances the agglomeration process between citric acid and magnesium oxide. 5
    [21] 21. A process according to any of claims 17 to 20 in which the citric acid is loaded in a single batch into the means for forming a homogeneous or substantially homogeneous mixture of compounds with markedly different densities, prior to addition of magnesium oxide. 10
    [22] 22. A process according to claim 21 in which the magnesium oxide is added to the single batch of citric acid in batches, with mixing between addition of each batch.
    [23] 23. A process according to claim 17 to 22 wherein the citric acid has a 15 particle size (diameter) range of between about 100 pm and about 900 Um.
    [24] 24. A composition comprising granules, which are agglomerated particles of citric acid and magnesium oxide. 20
    [25] 25. A composition comprising granules including citric acid and magnesium oxide, the granules comprising a layer of magnesium oxide coated on a core of citric acid. 25
    [26] 26. A composition according to claim 25 wherein the thickness of the layer of magnesium oxide is 2 to 15 pm.
    [27] 27. A composition according to claim 25 or 26 wherein the thickness of the layer of magnesium oxide is 5 to 10 pm. 30
    [28] 28. A composition according to any of claims 24 to 27 wherein the granules are between 450 and 800 pm broad at their broadest point. 26 WO 2009/047633 PCT/IB2008/003199
    [29] 29. A composition according to any of claims 24 to 28 wherein the granules have a particle size (diameter) range of between about 100 im and 900 pm. 5
    [30] 30. A composition according to any of claims 24 to 29 wherein the granules have a particle size (diameter) distribution wherein more than 85% of the particles have a particle size (diameter) between about 100 pm and about 900 pm. 10
    [31] 31. A composition according to any of claims 24 to 30 wherein the granules have a particle size (diameter) distribution wherein less than 5% of the particles have a particle size (diameter) greater than about 900 pm; and/or wherein less than 5% of the particles have a particle size (diameter) 15 less than about 100 im.
    [32] 32. A composition comprising citric acid and magnesium oxide formed by a process according to any of claims 18 to 23. 20
    [33] 33. A process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate and, optionally, saccharin sodium and/or orange flavour, comprising: a) dry mixing citric acid and magnesium oxide: 25 b) applying (e.g. spraying) a solution of sodium picosulphate onto the potassium bicarbonate; and drying said sodium picosulphate and potassium bicarbonate; and c) mixing at least a part of the product of step a) with at least a part of the product of step b) and, optionally, saccharin sodium and/or 30 orange flavour. 27 WO 2009/047633 PCT/IB2008/003199
    [34] 34. A process according to claim 33 in which step (a) includes a process according to any of claims 18 to 23.
    [35] 35. A process according to claim 33 or claim 34 in which step (b) 5 includes a process according to any of claims 3 to 11.
    [36] 36. A process for the preparation of a pharmaceutical composition according to any of claims 33 to 35 comprising a further step d) of mixing the product of step c) with further amount of a mixture formed by dry 10 mixing citric acid and magnesium oxide; and/or a product formed by applying (e.g. spraying) a solution of sodium picosulphate on to potassium bicarbonate and drying the sodium picosulphate and potassium bicarbonate. 15
    [37] 37. A process according to claim 36 wherein the further amount of a mixture of citric acid and magnesium oxide includes some or all of the product of step (a) and/or is formed by a process according to any of claims 18 to 23. 20
    [38] 38. A process according to claim 36 or 37 wherein the further amount of a product formed by applying (e.g. spraying) a solution of sodium picosulphate on to potassium bicarbonate and drying includes some or all of the product of step (b) and/or is formed by a process according to any of claims 3 to 11. 25
    [39] 39. A pharmaceutical preparation or composition comprising granules of a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate and, optionally, saccharin sodium and/or orange flavour. 30 28 WO 2009/047633 PCT/IB2008/003199
    [40] 40. A pharmaceutical composition according to claim 39 wherein the granules) have a particle size (diameter) range between about 100 and about 900 pm. 5
    [41] 41. A pharmaceutical composition according to claim 39 or claim 40 wherein the granule(s) have a uniformity of content of sodium picosulphate of mean value between about 0.0559% and 0.068% by weight.
    [42] 42. A pharmaceutical composition obtained by, or obtainable by, a 10 process according to any of claims 33 to 38.
    [43] 43. A pharmaceutical composition comprising product granules of a homogeneous or substantially homogeneous mixture of a first composition according to any of claims 24 to 32 comprising granules of citric acid and 15 magnesium oxide; and a second composition according to any of claims 12 to 16 comprising granules of potassium bicarbonate and sodium picosulphate; and, optionally, saccharin sodium and/or orange flavour.
    [44] 44. A pharmaceutical composition according to claim 43 wherein the 20 product granule(s) have a particle size (diameter) range between about 100 and about 900 pm.
    [45] 45. A pharmaceutical composition according to claim 43 or claim 44 wherein the product granule(s) have a uniformity of content of sodium 25 picosulphate of mean value between about 0.0559% and 0.068% by weight.
    [46] 46. A pharmaceutical composition according to any of claims 39 to 45 for use as a laxative,
    [47] 47. A composition according to claim 24 wherein the granules comprise 30 magnesium oxide coated on the citric acid. 29 WO 2009/047633 PCT/IB2008/003199
    [48] 48. A process according to claim 17 or claim 18 in which the means for forming a homogeneous mixture of compounds with markedly different densities is a bladeless and/or paddleless blender. 30
    类似技术:
    公开号 | 公开日 | 专利标题
    AU2008309287B2|2014-10-30|Process for the manufacure of a pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical composition comprising granules obtained by such process and intermediate
    JP4760381B2|2011-08-31|Solid preparation for dialysis and production method thereof
    US6923987B2|2005-08-02|Solid preparation for dialysis and process for producing the same
    KR20100028586A|2010-03-12|Solid dialysis preparation
    JP4603977B2|2010-12-22|Dialysis solid preparation and method for producing the same
    EP1192960B1|2003-11-12|Solid preparation for dialysis and process for producing the same
    AU2013204452B2|2016-08-11|Process for the manufacure of a pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical composition comprising granules obtained by such process and intermediate
    CN101406457A|2009-04-15|Process for the manufacture of a pharmaceutical product
    JP4483806B2|2010-06-16|Preparation for solid dialysis and method for producing the same
    US20160220544A1|2016-08-04|Pharmaceutical composition of sodium picosulfate
    JP4945917B2|2012-06-06|Core particles for drug-containing coatings
    JP2001149466A|2001-06-05|Solid sodium bicarbonate dialyzing agent and its preparation process
    JP2011213714A|2011-10-27|Manufacturing method of ibuprofen containing solid preparation
    JP2008007524A|2008-01-17|Solid sodium bicarbonate dialysis agent
    MXPA00009463A|2001-07-09|Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
    同族专利:
    公开号 | 公开日
    AU2013204452B2|2016-08-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    AUPN634595A0|1995-11-03|1995-11-30|Borody, Thomas Julius|Improved method for colonic evacuation|
    DE19962251A1|1999-12-22|2001-09-06|Hermes Fabrik Pharm Praeparate|Lozenge with thermally neutral dissolution properties containing active substance with exothermic dissolution behavior and compensatory adjuvant with endothermic dissolution behavior|
    法律状态:
    2016-12-08| FGA| Letters patent sealed or granted (standard patent)|
    优先权:
    申请号 | 申请日 | 专利标题
    EP07254049.5||2007-10-12||
    US60/980,549||2007-10-17||
    CN200710186023.6||2007-11-09||
    GB0805953.7||2008-04-01||
    AU2008309287A|AU2008309287B2|2007-10-12|2008-10-10|Process for the manufacure of a pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical composition comprising granules obtained by such process and intermediate|
    AU2013204452A|AU2013204452B2|2007-10-12|2013-04-12|Process for the manufacure of a pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical composition comprising granules obtained by such process and intermediate|AU2013204452A| AU2013204452B2|2007-10-12|2013-04-12|Process for the manufacure of a pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical composition comprising granules obtained by such process and intermediate|
    [返回顶部]